This article is more than 5 years old. Information may no longer be current.
LUMINOUS study: Ranibizumab improves visual acuity in treatment naïve patients at 1 year
Click Here to Manage Email Alerts
SEATTLE — Treatment naïve patients who were administered ranibizumab for neovascular age-related macular degeneration showed an improvement in visual acuity at 1 year, according to a poster presentation of the LUMINOUS study here.
“The presenting visual acuity and number of injections given determines the visual outcome. The better the presenting visual acuity, the better the outcome,” Christopher Brand, MD, told Ocular Surgery News in an interview at the Association for Research in Vision and Ophthalmology meeting. “If you want a good outcome at 12 months, you need to treat your patients early and give them injections.”
The LUMINOUS study is an ongoing 5-year, multicenter, global, observational study designed to evaluate the long-term safety, effectiveness, treatment patterns and health-related quality of life outcomes associated with Lucentis (ranibizumab, Genentech) treatment in routine clinical practices across all approved indications, Brand said.
The study included 17,656 wet AMD patients who were treatment naïve or previously treated with Lucentis or other ocular treatments; 4,497 were treatment naïve.
At baseline, mean visual acuity in the treatment naïve group was 49.9 letters and mean central retinal thickness was 360.6 µm.
At 1 year, mean change in visual acuity in the treatment naïve group was 3.6 lines. Patients who received fewer than three injections, three to six injections and more than six injections had visual acuity gains of 2.4 letters, 3.5 letters and 4.5 letters, respectively.
“Future follow-up data and country level analyses from the LUMINOUS study will provide invaluable information to optimize patient outcomes with ranibizumab treatment,” Brand said. – by Nhu Te
Reference:
Brand C. One-year outcomes with ranibizumab in treatment naïve patients with neovascular age-related macular degeneration: An interim analysis from the LUMINOUS study. Presented at: ARVO; May 1-5, 2016; Seattle, Washington.
Disclosure: Brand reports he has financial interests with Alcon, Allergan, Bayer Pharmaceuticals, Novartis, Oraya and Pfizer.